The Genetic Testing Reference Materials Coordination Program: Over 10 Years of Support for Pharmacogenomic Testing.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. PharmVar GeneFocus: NAT2-Genetic Variation and Updated Nomenclature.Clinical pharmacology and therapeutics · 2026
   Review
2. Population Genetics of Pharmacogenetic Variants in a Greek Psychiatric Cohort of over 3000 Individuals.International journal of molecular sciences · 2025
   Article
3. STRIPE partners in precision medicine: laboratory perspective.The pharmacogenomics journal · 2025
   Review
4. New Resources to Identify Characterized DNA Reference Materials for Pharmacogenetic (PGx) and Human Leukocyte Antigen (HLA) Testing: The Genetic Testing Reference Material (GeT-RM) Program PGx Search Tool and GeT-RM Consolidated PGx and HLA Table.The Journal of molecular diagnostics : JMD · 2025
   Article
5. PharmVar GeneFocus: CYP4F2.Clinical pharmacology and therapeutics · 2024
   Review

Corrections and comments

• Comment on
  Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative Project.2023

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as